DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $112.25.

Several research firms recently commented on DXCM. Royal Bank of Canada dropped their price target on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays lowered their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. BTIG Research cut their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Finally, Robert W. Baird raised their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th.

DexCom Stock Up 3.7 %

Shares of DXCM opened at $68.11 on Monday. The business’s 50 day simple moving average is $70.19 and its 200-day simple moving average is $105.15. DexCom has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market capitalization of $27.09 billion, a price-to-earnings ratio of 43.94, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business earned $0.34 earnings per share. DexCom’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, equities analysts expect that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,824 shares of company stock valued at $126,390. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Hedge funds have recently bought and sold shares of the stock. Bank of New Hampshire bought a new position in shares of DexCom in the 1st quarter worth $1,508,000. Waters Parkerson & CO. LLC raised its holdings in DexCom by 4.2% in the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares in the last quarter. Legal & General Group Plc lifted its position in shares of DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares during the last quarter. Mattson Financial Services LLC bought a new stake in shares of DexCom in the 2nd quarter valued at about $2,003,000. Finally, Los Angeles Capital Management LLC grew its position in shares of DexCom by 62.5% in the 1st quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock worth $49,520,000 after buying an additional 137,336 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.